ABCL·AbCellera Biologics Inc.

Realized volatility (21d)

62.2% 47th pct

Below its peak

-76.0%

vs 200-day average

+101.7%

Up days (1y)

49%

AbCellera Biologics Inc. is currently running 62.2% annualised volatility over the last 21 sessions. Measured against ABCL's own 6 years of daily returns rather than a market-wide average, that is the 47th percentile — close to its own typical level, against a typical reading of 64.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ABCL is trading -76.0% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -59.7%, and the deepest was -75.0% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +101.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year ABCL closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 6 years of records, ABCL finished the month higher 2 of 6 times, with a median return of -7.4% and an average of -3.1%. Its strongest month historically has been June at +10.5% on average, its weakest February at -11.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ABCL has opened more than 2% away from the prior close in 356 of 1,464 sessions (24.3% of the time), with the largest gaps running +12.4% and -13.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,465 daily closes between 2020-12-14 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ABCL's own 6-year history, not a peer group or index.